Barclays Remains a Buy on Twist Bioscience (TWST)

In a report issued on February 4, Luke Sergott from Barclays maintained a Buy rating on Twist Bioscience (TWSTResearch Report), with a price target of $75.00. The company’s shares closed last Friday at $59.50, close to its 52-week low of $48.63.

According to, Sergott is a 4-star analyst with an average return of 16.2% and a 53.1% success rate. Sergott covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, IQVIA Holdings, and Sotera Health.

Currently, the analyst consensus on Twist Bioscience is a Moderate Buy with an average price target of $99.33.

See today’s best-performing stocks on TipRanks >>

Twist Bioscience’s market cap is currently $3.02B and has a P/E ratio of -17.79.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Twist Bioscience Corp. develops proprietary semiconductor-based synthetic DNA manufacturing process. It produces synthetic biology tools such as genes, oligo pools, variant libraries, DNA data storage and NGS. The company also produces agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. Twist Bioscience was founded by William Marine Banyai, Emily Marine Leproust and Bill James Peck in February 2013 and is headquartered in San Francisco, CA.

Read More on TWST:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More